Acrylamides

Global Polyacrylamide Market Growth, Trends, COVID-19 Impact, and Forecasts 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 16, 2021
Chemicals, Plastics, Manufacturing, Acrylamides, Gels, Neurotoxins, Polyacrylamide, Polyelectrolytes, Compound annual growth rate, Chemistry, Academic disciplines, Matter

The "Polyacrylamide Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Polyacrylamide Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
  • The polyacrylamide market is expected to register a CAGR of more than 5% during the forecast period.
  • The polyacrylamide market is highly consolidated, with the major players accounting for a major share of the market.
  • The company generated ~80% of it's net revenue from the polyacrylamide business, and accounted for 48% of the global market.

X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021

Retrieved on: 
Friday, June 11, 2021
Chemical compounds, Branches of biology, Organic compounds, Tyrosine kinase inhibitors, Orphan drugs, Acrylamides, Breakthrough therapy, Ibrutinib, Pyrazolopyrimidines, CXCR4, MYD88

We are very pleased to present this exciting first look at the data from our ongoing Phase 1b trial in double-mutation Waldenstrms patients, said Diego Cadavid, M.D., Chief Medical Officer of X4 Pharmaceuticals.

Key Points: 
  • We are very pleased to present this exciting first look at the data from our ongoing Phase 1b trial in double-mutation Waldenstrms patients, said Diego Cadavid, M.D., Chief Medical Officer of X4 Pharmaceuticals.
  • We look forward to presenting longer-term data and an expanded data set from this trial later in the year.
  • Mavorixafor exposures tracked with sustained and dose-dependent increases in white blood cell counts, confirming target engagement and mavorixafor mechanism of action.
  • The e-poster (EP784) entitled: Preliminary Clinical Data From a Phase 1b Study of Mavorixafor and Ibrutinib in Patients With Waldenstrms Macroglobulinemia With MYD88 and CXCR4 Mutations is now available on the X4 corporate website .

CALQUENCE Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients With Chronic Lymphocytic Leukemia and Sustained Patient Benefit at Four Years in the Front-line Setting

Retrieved on: 
Monday, June 7, 2021
Oncology, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Orphan drugs, Tyrosine kinase inhibitors, Clinical medicine, Organic compounds, Drugs, Cardiac arrhythmia, Acrylamides, Ibrutinib, Pyrazolopyrimidines, Acalabrutinib, Chronic lymphocytic leukemia, Atrial fibrillation

In clinical trials, major hemorrhage occurred in 2.7% of patients taking CALQUENCE without antithrombotic agents and 3.6% of patients taking CALQUENCE with antithrombotic agents.

Key Points: 
  • In clinical trials, major hemorrhage occurred in 2.7% of patients taking CALQUENCE without antithrombotic agents and 3.6% of patients taking CALQUENCE with antithrombotic agents.
  • Grade 3 or 4 cytopenias, including neutropenia (23%), anemia (8%), thrombocytopenia (7%), and lymphopenia (7%), developed in patients with hematologic malignancies treated with CALQUENCE.
  • Grade 3 atrial fibrillation or flutter occurred in 1.1% of 1029 patients treated with CALQUENCE, with all grades of atrial fibrillation or flutter reported in 4.1% of all patients.
  • First Results of a Head-to-Head Trial of Acalabrutinib versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia.

Polyacrylamide (CAS 9003-05-8) Global Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 1, 2021
Chemicals, Plastics, Manufacturing, Acrylamides, Gels, Neurotoxins, Polyacrylamide, Polyelectrolytes, Chemistry, Matter, Chemical substances

The "Polyacrylamide (CAS 9003-05-8) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Polyacrylamide (CAS 9003-05-8) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Polyacrylamide.
  • The fifth chapter deals with Polyacrylamide market trends and forecast, distinguish Polyacrylamide manufacturers and suppliers.
  • The Polyacrylamide global market report key points:

China Ibrutinib Market Report 2021: By 2020, Pharmacyclics Inc is the Only Manufacturer in the Chinese Market - Forecast to 2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 20, 2021
Health, Pharmaceutical, Chemical compounds, Countries, Organic compounds, Orphan drugs, Tyrosine kinase inhibitors, Breakthrough therapy, Acrylamides, Ibrutinib, Pyrazolopyrimidines, Economy of China, China

Their Ibrutinib, IMBRUVICA was launched in China in 2017.\nAccording to this market research, after Ibrutinib entered the Chinese market, the sales value of Ibrutinib in China has increased from CNY48,600 in 2017 to CNY 345.5 million in 2020.

Key Points: 
  • Their Ibrutinib, IMBRUVICA was launched in China in 2017.\nAccording to this market research, after Ibrutinib entered the Chinese market, the sales value of Ibrutinib in China has increased from CNY48,600 in 2017 to CNY 345.5 million in 2020.
  • In 2020, the growth rate was 38.2%, which slowed down due to the COVID-19 epidemic.
  • On the other hand, China approves fewer indications for Ibrutinib than other countries do.
  • Therefore, the number of approved indications has the potential to increase, which means the market will keep expanding in the future.\n2 Sales of Ibrutinib in China, 2017-2020\n2.3 Sales of Ibrutinib by Dosage Form in China, 2017-2020\n3 Analysis of Major Ibrutinib Manufacturers in China, 2017-2020\n4 Prices of Ibrutinib for Different Manufacturers in China, 2020-2021\n5 Prospect of Chinese Ibrutinib drug Market, 2021-2025\n'

Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib at ASCO 2021

Retrieved on: 
Wednesday, May 19, 2021
Drugs, Orphan drugs, Chemical compounds, Tyrosine kinase inhibitors, Organic compounds, Breakthrough therapy, Acrylamides, Ibrutinib, Piperidines, Chronic lymphocytic leukemia, WNT5A, ROR1

Adding cirmtuzumab to ibrutinib appears well tolerated, with no apparent additional toxicities noted to date,\xe2\x80\x9d said James Breitmeyer, M.D., Ph.D., Oncternal\xe2\x80\x99s President and CEO.

Key Points: 
  • Adding cirmtuzumab to ibrutinib appears well tolerated, with no apparent additional toxicities noted to date,\xe2\x80\x9d said James Breitmeyer, M.D., Ph.D., Oncternal\xe2\x80\x99s President and CEO.
  • Preclinical data showed that when cirmtuzumab bound to ROR1, it blocked Wnt5a signaling, inhibited tumor cell proliferation, migration and survival, and induced differentiation of the tumor cells.
  • The FDA has granted Orphan Drug Designations to cirmtuzumab for the treatment of MCL and CLL/small lymphocytic lymphoma.
  • This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.\n'

IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control

Retrieved on: 
Wednesday, May 19, 2021
Chemical compounds, Organic compounds, Breakthrough therapy, Orphan drugs, Tyrosine kinase inhibitors, Health sciences, Acrylamides, Ibrutinib, Pyrazolopyrimidines, Bruton's tyrosine kinase, Pneumocystis pneumonia, PML

For more information, visit www.IMBRUVICA.com .\nHemorrhage: Fatal bleeding events have occurred in patients who received IMBRUVICA.

Key Points: 
  • For more information, visit www.IMBRUVICA.com .\nHemorrhage: Fatal bleeding events have occurred in patients who received IMBRUVICA.
  • Cases of progressive multifocal leukoencephalopathy (PML) and Pneumocystis jirovecii pneumonia (PJP) have occurred in patients treated with IMBRUVICA.
  • Up to 7 Years of Follow-up in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Patients With Chronic Lymphocytic Leukemia.
  • The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Wednesday, March 10, 2021
Chemical compounds, Organic compounds, Drugs, Acrylamides, Breakthrough therapy, Ibrutinib, Piperidines, Pyrazolopyrimidines, Bruton's tyrosine kinase, Acute myeloid leukemia, Oncology, Cancer immunotherapy

Details of the presentation are as follows:

Key Points: 
  • Details of the presentation are as follows:
    Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer.
  • In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology.
  • CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination with BTK inhibitor, ibrutinib.
  • Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes.

SNF Continues Investment in the USA to Meet Polyacrylamide (PAM) Demand

Retrieved on: 
Wednesday, February 10, 2021
Acrylamides, Gels, Neurotoxins, Polyacrylamide, Polyelectrolytes, SNF, Chemistry, Matter, Chemical substances

RICEBORO, Ga., Feb. 10, 2021 /PRNewswire/ --SNF will invest $300 Million in the USA in 2021-2022 for an additional 30,000 MT/yr.

Key Points: 
  • RICEBORO, Ga., Feb. 10, 2021 /PRNewswire/ --SNF will invest $300 Million in the USA in 2021-2022 for an additional 30,000 MT/yr.
  • The previously announced $1.2 Billion investment to expand Polyacrylamide (PAM) production worldwide is in the final stages of completion.
  • This has resulted in additional capacity in all key product areas and logistics for SNF's USA operations.
  • A pioneer in soft chemistry, SNF has long been present on all continents, employing 6,500 people, including 1,800 in the USA.

Biocompatible Materials Market to Reach US$ 347 Bn by 2030; COVID-19 Restrictions to Moderately Affect Growth Prospects in Near Term - Persistence Market Research

Retrieved on: 
Friday, January 22, 2021
Biomolecules, Acrylamides, Monomers, N-(2-Hydroxypropyl) methacrylamide, Biomaterial, Chemistry, Natural sciences

Hence, increasing investments by companies for advanced product development that are non-toxic and non-immunogenic are also expected to create growth opportunities for the biocompatible materials market .

Key Points: 
  • Hence, increasing investments by companies for advanced product development that are non-toxic and non-immunogenic are also expected to create growth opportunities for the biocompatible materials market .
  • According to a latest report published by PERSISTENCE MARKET RESEARCH, the global biocompatible materials market is anticipated to experience a CAGR of over 9% during the forecast period (2020 2030).
  • The synthetic polymers segment, under material type, is expected to hold significant revenue share in the biocompatible materials market.
  • In terms of regional growth, North America, Europe, and Asia Pacific are manufacturing hubs for biocompatible materials, and are anticipated to witness rapid growth in the global biocompatible materials market.